UnitedHealth takeover of EMIS referred for UK in-depth antitrust probe
Reuters
Published Mar 31, 2023 07:51
Updated Mar 31, 2023 15:41
(Corrects to read June (not July), paragraph 7)
(Reuters) -Britain's competition watchdog said on Friday it would refer UnitedHealth (NYSE:UNH) Group's 1.24 billion pound ($1.54 billion) acquisition of healthcare technology firm EMIS for a Phase 2 investigation.
The Competition and Markets Authority (CMA) said it had rejected a remedy offered by U.S.-based UnitedHealth after deeming it did not go far enough in mitigating the potential competitive impact of the combination.
The proposed remedy was a divestiture of the domestic Medicines Optimisation and Population Health Management businesses of Optum UK, part of UnitedHealth.
EMIS said the merging parties disagreed with the decision and were weighing their next steps.
"(We) are disappointed with the CMA's decision and continue to believe that the proposed remedy directly addresses the competition concerns raised by the CMA following its Phase 1 investigation," the company said.
"Optum UK and EMIS are currently considering their options and will provide a further update with regards to the acquisition in due course."
UnitedHealth unveiled an offer to acquire EMIS in June, in a move aimed at positioning the combined entity to provide better services to Britain's National Health Service (NHS).
The CMA launched its initial merger enquiry in January and warned the parties earlier in March that it would subject the deal to further scrutiny if they failed to offer acceptable remedies.
($1 = 0.8073 pounds)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.